http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 26 Jun 2026 09:01:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Nippon+Shinyaku+and+Elixirgen+Therapeutics+Enter+Option+Agreement+for+Development+and+Commercialization+of+EXG-7001+for+Duchenne+Muscular+Dystrophy/26695545.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.parmus" idsrc="xmltag.org" >PARAMUS, N.J.</location></span>, <span class="legendSpanClass"><chron>June 26, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1422978886" idsrc="xmltag.org" >NS Pharma, Inc.</span> (NS Pharma; Headquarters, <location value="LU/us.nj.parmus" idsrc="xmltag.org" >Paramus, NJ</location>; President, <person>Yukiteru Sugiyama</person>) announced today that its parent company, <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku Co., Ltd.</span> (<span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span>; Headquarters, <location value="LU/jp..kyoto" idsrc="xmltag.org" >Kyoto, Japan</location>; President, <person>Toru Nakai</person>) has entered into an option agreement with <span value="ACORN:5021692585" idsrc="xmltag.org" >Elixirgen Therapeutics, Inc.</span> (Elixirgen; Headquarters, <location value="LU/us.md.bltmre" idsrc="xmltag.org" >Baltimore, MD</location>; CEO, <person>Aki Ko</person>) under which <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span> may obtain the exclusive worldwide rights to develop and commercialize EXG-7001 for the http://www.streetinsider.com/Press+Releases/Nippon+Shinyaku+and+Elixirgen+Therapeutics+Enter+Option+Agreement+for+Development+and+Commercialization+of+EXG-7001+for+Duchenne+Muscular+Dystrophy/26695545.html Fri, 26 Jun 2026 09:01:00 -0400 4516 A.14229788 A.50216925 NPPNY O.02298954 O.05105676 O.21971128 http://www.streetinsider.com/Press+Releases/Nippon+Shinyaku+and+Elixirgen+Therapeutics+Enter+Option+Agreement+for+Development+and+Commercialization+of+EXG-7001+for+Duchenne+Muscular+Dystrophy/26695545.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.parmus" idsrc="xmltag.org" >PARAMUS, N.J.</location></span>, <span class="legendSpanClass"><chron>June 26, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1422978886" idsrc="xmltag.org" >NS Pharma, Inc.</span> (NS Pharma; Headquarters, <location value="LU/us.nj.parmus" idsrc="xmltag.org" >Paramus, NJ</location>; President, <person>Yukiteru Sugiyama</person>) announced today that its parent company, <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku Co., Ltd.</span> (<span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span>; Headquarters, <location value="LU/jp..kyoto" idsrc="xmltag.org" >Kyoto, Japan</location>; President, <person>Toru Nakai</person>) has entered into an option agreement with <span value="ACORN:5021692585" idsrc="xmltag.org" >Elixirgen Therapeutics, Inc.</span> (Elixirgen; Headquarters, <location value="LU/us.md.bltmre" idsrc="xmltag.org" >Baltimore, MD</location>; CEO, <person>Aki Ko</person>) under which <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span> may obtain the exclusive worldwide rights to develop and commercialize EXG-7001 for the http://www.streetinsider.com/Press+Releases/Nippon+Shinyaku+and+Elixirgen+Therapeutics+Enter+Option+Agreement+for+Development+and+Commercialization+of+EXG-7001+for+Duchenne+Muscular+Dystrophy/26695545.html Fri, 26 Jun 2026 09:01:00 -0400 4516 A.14229788 A.50216925 NPPNY O.02298954 O.05105676 O.21971128 http://www.streetinsider.com/Press+Releases/Nippon+Shinyaku+and+Elixirgen+Therapeutics+Enter+Option+Agreement+for+Development+and+Commercialization+of+EXG-7001+for+Duchenne+Muscular+Dystrophy/26695545.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.parmus" idsrc="xmltag.org" >PARAMUS, N.J.</location></span>, <span class="legendSpanClass"><chron>June 26, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1422978886" idsrc="xmltag.org" >NS Pharma, Inc.</span> (NS Pharma; Headquarters, <location value="LU/us.nj.parmus" idsrc="xmltag.org" >Paramus, NJ</location>; President, <person>Yukiteru Sugiyama</person>) announced today that its parent company, <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku Co., Ltd.</span> (<span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span>; Headquarters, <location value="LU/jp..kyoto" idsrc="xmltag.org" >Kyoto, Japan</location>; President, <person>Toru Nakai</person>) has entered into an option agreement with <span value="ACORN:5021692585" idsrc="xmltag.org" >Elixirgen Therapeutics, Inc.</span> (Elixirgen; Headquarters, <location value="LU/us.md.bltmre" idsrc="xmltag.org" >Baltimore, MD</location>; CEO, <person>Aki Ko</person>) under which <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span> may obtain the exclusive worldwide rights to develop and commercialize EXG-7001 for the http://www.streetinsider.com/Press+Releases/Nippon+Shinyaku+and+Elixirgen+Therapeutics+Enter+Option+Agreement+for+Development+and+Commercialization+of+EXG-7001+for+Duchenne+Muscular+Dystrophy/26695545.html Fri, 26 Jun 2026 09:01:00 -0400 4516 A.14229788 A.50216925 NPPNY O.02298954 O.05105676 O.21971128 http://www.streetinsider.com/Press+Releases/Nippon+Shinyaku+and+Elixirgen+Therapeutics+Enter+Option+Agreement+for+Development+and+Commercialization+of+EXG-7001+for+Duchenne+Muscular+Dystrophy/26695545.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.parmus" idsrc="xmltag.org" >PARAMUS, N.J.</location></span>, <span class="legendSpanClass"><chron>June 26, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1422978886" idsrc="xmltag.org" >NS Pharma, Inc.</span> (NS Pharma; Headquarters, <location value="LU/us.nj.parmus" idsrc="xmltag.org" >Paramus, NJ</location>; President, <person>Yukiteru Sugiyama</person>) announced today that its parent company, <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku Co., Ltd.</span> (<span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span>; Headquarters, <location value="LU/jp..kyoto" idsrc="xmltag.org" >Kyoto, Japan</location>; President, <person>Toru Nakai</person>) has entered into an option agreement with <span value="ACORN:5021692585" idsrc="xmltag.org" >Elixirgen Therapeutics, Inc.</span> (Elixirgen; Headquarters, <location value="LU/us.md.bltmre" idsrc="xmltag.org" >Baltimore, MD</location>; CEO, <person>Aki Ko</person>) under which <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span> may obtain the exclusive worldwide rights to develop and commercialize EXG-7001 for the http://www.streetinsider.com/Press+Releases/Nippon+Shinyaku+and+Elixirgen+Therapeutics+Enter+Option+Agreement+for+Development+and+Commercialization+of+EXG-7001+for+Duchenne+Muscular+Dystrophy/26695545.html Fri, 26 Jun 2026 09:01:00 -0400 4516 A.14229788 A.50216925 NPPNY O.02298954 O.05105676 O.21971128 http://www.streetinsider.com/Press+Releases/Nippon+Shinyaku+and+Elixirgen+Therapeutics+Enter+Option+Agreement+for+Development+and+Commercialization+of+EXG-7001+for+Duchenne+Muscular+Dystrophy/26695545.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.parmus" idsrc="xmltag.org" >PARAMUS, N.J.</location></span>, <span class="legendSpanClass"><chron>June 26, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1422978886" idsrc="xmltag.org" >NS Pharma, Inc.</span> (NS Pharma; Headquarters, <location value="LU/us.nj.parmus" idsrc="xmltag.org" >Paramus, NJ</location>; President, <person>Yukiteru Sugiyama</person>) announced today that its parent company, <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku Co., Ltd.</span> (<span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span>; Headquarters, <location value="LU/jp..kyoto" idsrc="xmltag.org" >Kyoto, Japan</location>; President, <person>Toru Nakai</person>) has entered into an option agreement with <span value="ACORN:5021692585" idsrc="xmltag.org" >Elixirgen Therapeutics, Inc.</span> (Elixirgen; Headquarters, <location value="LU/us.md.bltmre" idsrc="xmltag.org" >Baltimore, MD</location>; CEO, <person>Aki Ko</person>) under which <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span> may obtain the exclusive worldwide rights to develop and commercialize EXG-7001 for the http://www.streetinsider.com/Press+Releases/Nippon+Shinyaku+and+Elixirgen+Therapeutics+Enter+Option+Agreement+for+Development+and+Commercialization+of+EXG-7001+for+Duchenne+Muscular+Dystrophy/26695545.html Fri, 26 Jun 2026 09:01:00 -0400 4516 A.14229788 A.50216925 NPPNY O.02298954 O.05105676 O.21971128 http://www.streetinsider.com/Press+Releases/Nippon+Shinyaku+and+Elixirgen+Therapeutics+Enter+Option+Agreement+for+Development+and+Commercialization+of+EXG-7001+for+Duchenne+Muscular+Dystrophy/26695545.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.parmus" idsrc="xmltag.org" >PARAMUS, N.J.</location></span>, <span class="legendSpanClass"><chron>June 26, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1422978886" idsrc="xmltag.org" >NS Pharma, Inc.</span> (NS Pharma; Headquarters, <location value="LU/us.nj.parmus" idsrc="xmltag.org" >Paramus, NJ</location>; President, <person>Yukiteru Sugiyama</person>) announced today that its parent company, <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku Co., Ltd.</span> (<span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span>; Headquarters, <location value="LU/jp..kyoto" idsrc="xmltag.org" >Kyoto, Japan</location>; President, <person>Toru Nakai</person>) has entered into an option agreement with <span value="ACORN:5021692585" idsrc="xmltag.org" >Elixirgen Therapeutics, Inc.</span> (Elixirgen; Headquarters, <location value="LU/us.md.bltmre" idsrc="xmltag.org" >Baltimore, MD</location>; CEO, <person>Aki Ko</person>) under which <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span> may obtain the exclusive worldwide rights to develop and commercialize EXG-7001 for the http://www.streetinsider.com/Press+Releases/Nippon+Shinyaku+and+Elixirgen+Therapeutics+Enter+Option+Agreement+for+Development+and+Commercialization+of+EXG-7001+for+Duchenne+Muscular+Dystrophy/26695545.html Fri, 26 Jun 2026 09:01:00 -0400 4516 A.14229788 A.50216925 NPPNY O.02298954 O.05105676 O.21971128 http://www.streetinsider.com/Press+Releases/Nippon+Shinyaku+and+Elixirgen+Therapeutics+Enter+Option+Agreement+for+Development+and+Commercialization+of+EXG-7001+for+Duchenne+Muscular+Dystrophy/26695545.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.parmus" idsrc="xmltag.org" >PARAMUS, N.J.</location></span>, <span class="legendSpanClass"><chron>June 26, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1422978886" idsrc="xmltag.org" >NS Pharma, Inc.</span> (NS Pharma; Headquarters, <location value="LU/us.nj.parmus" idsrc="xmltag.org" >Paramus, NJ</location>; President, <person>Yukiteru Sugiyama</person>) announced today that its parent company, <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku Co., Ltd.</span> (<span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span>; Headquarters, <location value="LU/jp..kyoto" idsrc="xmltag.org" >Kyoto, Japan</location>; President, <person>Toru Nakai</person>) has entered into an option agreement with <span value="ACORN:5021692585" idsrc="xmltag.org" >Elixirgen Therapeutics, Inc.</span> (Elixirgen; Headquarters, <location value="LU/us.md.bltmre" idsrc="xmltag.org" >Baltimore, MD</location>; CEO, <person>Aki Ko</person>) under which <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span> may obtain the exclusive worldwide rights to develop and commercialize EXG-7001 for the http://www.streetinsider.com/Press+Releases/Nippon+Shinyaku+and+Elixirgen+Therapeutics+Enter+Option+Agreement+for+Development+and+Commercialization+of+EXG-7001+for+Duchenne+Muscular+Dystrophy/26695545.html Fri, 26 Jun 2026 09:01:00 -0400 4516 A.14229788 A.50216925 NPPNY O.02298954 O.05105676 O.21971128 http://www.streetinsider.com/PRNewswire/Nippon+Shinyaku+and+Elixirgen+Therapeutics+Enter+Option+Agreement+for+Development+and+Commercialization+of+EXG-7001+for+Duchenne+Muscular+Dystrophy/26695545.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.parmus" idsrc="xmltag.org" >PARAMUS, N.J.</location></span>, <span class="legendSpanClass"><chron>June 26, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1422978886" idsrc="xmltag.org" >NS Pharma, Inc.</span> (NS Pharma; Headquarters, <location value="LU/us.nj.parmus" idsrc="xmltag.org" >Paramus, NJ</location>; President, <person>Yukiteru Sugiyama</person>) announced today that its parent company, <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku Co., Ltd.</span> (<span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span>; Headquarters, <location value="LU/jp..kyoto" idsrc="xmltag.org" >Kyoto, Japan</location>; President, <person>Toru Nakai</person>) has entered into an option agreement with <span value="ACORN:5021692585" idsrc="xmltag.org" >Elixirgen Therapeutics, Inc.</span> (Elixirgen; Headquarters, <location value="LU/us.md.bltmre" idsrc="xmltag.org" >Baltimore, MD</location>; CEO, <person>Aki Ko</person>) under which <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span> may obtain the exclusive worldwide rights to develop and commercialize EXG-7001 for the http://www.streetinsider.com/PRNewswire/Nippon+Shinyaku+and+Elixirgen+Therapeutics+Enter+Option+Agreement+for+Development+and+Commercialization+of+EXG-7001+for+Duchenne+Muscular+Dystrophy/26695545.html Fri, 26 Jun 2026 09:01:00 -0400 4516 A.14229788 A.50216925 NPPNY O.02298954 O.05105676 O.21971128 http://www.streetinsider.com/PRNewswire/Nippon+Shinyaku+and+Elixirgen+Therapeutics+Enter+Option+Agreement+for+Development+and+Commercialization+of+EXG-7001+for+Duchenne+Muscular+Dystrophy/26695545.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.parmus" idsrc="xmltag.org" >PARAMUS, N.J.</location></span>, <span class="legendSpanClass"><chron>June 26, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1422978886" idsrc="xmltag.org" >NS Pharma, Inc.</span> (NS Pharma; Headquarters, <location value="LU/us.nj.parmus" idsrc="xmltag.org" >Paramus, NJ</location>; President, <person>Yukiteru Sugiyama</person>) announced today that its parent company, <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku Co., Ltd.</span> (<span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span>; Headquarters, <location value="LU/jp..kyoto" idsrc="xmltag.org" >Kyoto, Japan</location>; President, <person>Toru Nakai</person>) has entered into an option agreement with <span value="ACORN:5021692585" idsrc="xmltag.org" >Elixirgen Therapeutics, Inc.</span> (Elixirgen; Headquarters, <location value="LU/us.md.bltmre" idsrc="xmltag.org" >Baltimore, MD</location>; CEO, <person>Aki Ko</person>) under which <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span> may obtain the exclusive worldwide rights to develop and commercialize EXG-7001 for the http://www.streetinsider.com/PRNewswire/Nippon+Shinyaku+and+Elixirgen+Therapeutics+Enter+Option+Agreement+for+Development+and+Commercialization+of+EXG-7001+for+Duchenne+Muscular+Dystrophy/26695545.html Fri, 26 Jun 2026 09:01:00 -0400 4516 A.14229788 A.50216925 NPPNY O.02298954 O.05105676 O.21971128 http://www.streetinsider.com/PRNewswire/Nippon+Shinyaku+and+Elixirgen+Therapeutics+Enter+Option+Agreement+for+Development+and+Commercialization+of+EXG-7001+for+Duchenne+Muscular+Dystrophy/26695545.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.parmus" idsrc="xmltag.org" >PARAMUS, N.J.</location></span>, <span class="legendSpanClass"><chron>June 26, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1422978886" idsrc="xmltag.org" >NS Pharma, Inc.</span> (NS Pharma; Headquarters, <location value="LU/us.nj.parmus" idsrc="xmltag.org" >Paramus, NJ</location>; President, <person>Yukiteru Sugiyama</person>) announced today that its parent company, <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku Co., Ltd.</span> (<span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span>; Headquarters, <location value="LU/jp..kyoto" idsrc="xmltag.org" >Kyoto, Japan</location>; President, <person>Toru Nakai</person>) has entered into an option agreement with <span value="ACORN:5021692585" idsrc="xmltag.org" >Elixirgen Therapeutics, Inc.</span> (Elixirgen; Headquarters, <location value="LU/us.md.bltmre" idsrc="xmltag.org" >Baltimore, MD</location>; CEO, <person>Aki Ko</person>) under which <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span> may obtain the exclusive worldwide rights to develop and commercialize EXG-7001 for the http://www.streetinsider.com/PRNewswire/Nippon+Shinyaku+and+Elixirgen+Therapeutics+Enter+Option+Agreement+for+Development+and+Commercialization+of+EXG-7001+for+Duchenne+Muscular+Dystrophy/26695545.html Fri, 26 Jun 2026 09:01:00 -0400 4516 A.14229788 A.50216925 NPPNY O.02298954 O.05105676 O.21971128 http://www.streetinsider.com/PRNewswire/Nippon+Shinyaku+and+Elixirgen+Therapeutics+Enter+Option+Agreement+for+Development+and+Commercialization+of+EXG-7001+for+Duchenne+Muscular+Dystrophy/26695545.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.parmus" idsrc="xmltag.org" >PARAMUS, N.J.</location></span>, <span class="legendSpanClass"><chron>June 26, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1422978886" idsrc="xmltag.org" >NS Pharma, Inc.</span> (NS Pharma; Headquarters, <location value="LU/us.nj.parmus" idsrc="xmltag.org" >Paramus, NJ</location>; President, <person>Yukiteru Sugiyama</person>) announced today that its parent company, <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku Co., Ltd.</span> (<span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span>; Headquarters, <location value="LU/jp..kyoto" idsrc="xmltag.org" >Kyoto, Japan</location>; President, <person>Toru Nakai</person>) has entered into an option agreement with <span value="ACORN:5021692585" idsrc="xmltag.org" >Elixirgen Therapeutics, Inc.</span> (Elixirgen; Headquarters, <location value="LU/us.md.bltmre" idsrc="xmltag.org" >Baltimore, MD</location>; CEO, <person>Aki Ko</person>) under which <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span> may obtain the exclusive worldwide rights to develop and commercialize EXG-7001 for the http://www.streetinsider.com/PRNewswire/Nippon+Shinyaku+and+Elixirgen+Therapeutics+Enter+Option+Agreement+for+Development+and+Commercialization+of+EXG-7001+for+Duchenne+Muscular+Dystrophy/26695545.html Fri, 26 Jun 2026 09:01:00 -0400 4516 A.14229788 A.50216925 NPPNY O.02298954 O.05105676 O.21971128 http://www.streetinsider.com/PRNewswire/Nippon+Shinyaku+and+Elixirgen+Therapeutics+Enter+Option+Agreement+for+Development+and+Commercialization+of+EXG-7001+for+Duchenne+Muscular+Dystrophy/26695545.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.parmus" idsrc="xmltag.org" >PARAMUS, N.J.</location></span>, <span class="legendSpanClass"><chron>June 26, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1422978886" idsrc="xmltag.org" >NS Pharma, Inc.</span> (NS Pharma; Headquarters, <location value="LU/us.nj.parmus" idsrc="xmltag.org" >Paramus, NJ</location>; President, <person>Yukiteru Sugiyama</person>) announced today that its parent company, <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku Co., Ltd.</span> (<span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span>; Headquarters, <location value="LU/jp..kyoto" idsrc="xmltag.org" >Kyoto, Japan</location>; President, <person>Toru Nakai</person>) has entered into an option agreement with <span value="ACORN:5021692585" idsrc="xmltag.org" >Elixirgen Therapeutics, Inc.</span> (Elixirgen; Headquarters, <location value="LU/us.md.bltmre" idsrc="xmltag.org" >Baltimore, MD</location>; CEO, <person>Aki Ko</person>) under which <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span> may obtain the exclusive worldwide rights to develop and commercialize EXG-7001 for the http://www.streetinsider.com/PRNewswire/Nippon+Shinyaku+and+Elixirgen+Therapeutics+Enter+Option+Agreement+for+Development+and+Commercialization+of+EXG-7001+for+Duchenne+Muscular+Dystrophy/26695545.html Fri, 26 Jun 2026 09:01:00 -0400 4516 A.14229788 A.50216925 NPPNY O.02298954 O.05105676 O.21971128 http://www.streetinsider.com/PRNewswire/Nippon+Shinyaku+and+Elixirgen+Therapeutics+Enter+Option+Agreement+for+Development+and+Commercialization+of+EXG-7001+for+Duchenne+Muscular+Dystrophy/26695545.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.parmus" idsrc="xmltag.org" >PARAMUS, N.J.</location></span>, <span class="legendSpanClass"><chron>June 26, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1422978886" idsrc="xmltag.org" >NS Pharma, Inc.</span> (NS Pharma; Headquarters, <location value="LU/us.nj.parmus" idsrc="xmltag.org" >Paramus, NJ</location>; President, <person>Yukiteru Sugiyama</person>) announced today that its parent company, <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku Co., Ltd.</span> (<span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span>; Headquarters, <location value="LU/jp..kyoto" idsrc="xmltag.org" >Kyoto, Japan</location>; President, <person>Toru Nakai</person>) has entered into an option agreement with <span value="ACORN:5021692585" idsrc="xmltag.org" >Elixirgen Therapeutics, Inc.</span> (Elixirgen; Headquarters, <location value="LU/us.md.bltmre" idsrc="xmltag.org" >Baltimore, MD</location>; CEO, <person>Aki Ko</person>) under which <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span> may obtain the exclusive worldwide rights to develop and commercialize EXG-7001 for the http://www.streetinsider.com/PRNewswire/Nippon+Shinyaku+and+Elixirgen+Therapeutics+Enter+Option+Agreement+for+Development+and+Commercialization+of+EXG-7001+for+Duchenne+Muscular+Dystrophy/26695545.html Fri, 26 Jun 2026 09:01:00 -0400 4516 A.14229788 A.50216925 NPPNY O.02298954 O.05105676 O.21971128 http://www.streetinsider.com/PRNewswire/Nippon+Shinyaku+and+Elixirgen+Therapeutics+Enter+Option+Agreement+for+Development+and+Commercialization+of+EXG-7001+for+Duchenne+Muscular+Dystrophy/26695545.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.parmus" idsrc="xmltag.org" >PARAMUS, N.J.</location></span>, <span class="legendSpanClass"><chron>June 26, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1422978886" idsrc="xmltag.org" >NS Pharma, Inc.</span> (NS Pharma; Headquarters, <location value="LU/us.nj.parmus" idsrc="xmltag.org" >Paramus, NJ</location>; President, <person>Yukiteru Sugiyama</person>) announced today that its parent company, <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku Co., Ltd.</span> (<span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span>; Headquarters, <location value="LU/jp..kyoto" idsrc="xmltag.org" >Kyoto, Japan</location>; President, <person>Toru Nakai</person>) has entered into an option agreement with <span value="ACORN:5021692585" idsrc="xmltag.org" >Elixirgen Therapeutics, Inc.</span> (Elixirgen; Headquarters, <location value="LU/us.md.bltmre" idsrc="xmltag.org" >Baltimore, MD</location>; CEO, <person>Aki Ko</person>) under which <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span> may obtain the exclusive worldwide rights to develop and commercialize EXG-7001 for the http://www.streetinsider.com/PRNewswire/Nippon+Shinyaku+and+Elixirgen+Therapeutics+Enter+Option+Agreement+for+Development+and+Commercialization+of+EXG-7001+for+Duchenne+Muscular+Dystrophy/26695545.html Fri, 26 Jun 2026 09:01:00 -0400 4516 A.14229788 A.50216925 NPPNY O.02298954 O.05105676 O.21971128 http://www.streetinsider.com/Press+Releases/NS+Pharma+Parent+Company%2C+Nippon+Shinyaku%2C+Announces+Sponsored+Research+Agreement+with+Boston+Children%27s+Hospital/26675765.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.parmus" idsrc="xmltag.org" >PARAMUS, N.J.</location></span>, <span class="legendSpanClass"><chron>June 23, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1422978886" idsrc="xmltag.org" >NS Pharma, Inc.</span> (NS Pharma; Headquarters: <location value="LU/us.nj.parmus" idsrc="xmltag.org" >Paramus, New Jersey</location>; President: <person>Yukiteru Sugiyama</person>) announced today that its parent company, <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku Co., Ltd.</span> (<span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span>; Headquarters: <location value="LU/jp..kyoto" idsrc="xmltag.org" >Kyoto, Japan</location>; President: <person>Toru Nakai</person>), has entered into a Sponsored Research Agreement (SRA) with <span value="ACORN:5020182014" idsrc="xmltag.org" >Boston Children's Hospital</span> (Headquarters: <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston, Massachusetts</location>; Chief Executive Officer: <person>Kevin B. Churchwell</person>) for the purpose of developing innovative therapeutic drugs in the field of neurology. The agreement http://www.streetinsider.com/Press+Releases/NS+Pharma+Parent+Company%2C+Nippon+Shinyaku%2C+Announces+Sponsored+Research+Agreement+with+Boston+Children%27s+Hospital/26675765.html Tue, 23 Jun 2026 07:13:00 -0400 4516 A.14229788 A.50201820 B NPPNY O.02298954 O.05105676 O.20314535 http://www.streetinsider.com/Press+Releases/NS+Pharma+Parent+Company%2C+Nippon+Shinyaku%2C+Announces+Sponsored+Research+Agreement+with+Boston+Children%27s+Hospital/26675765.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.parmus" idsrc="xmltag.org" >PARAMUS, N.J.</location></span>, <span class="legendSpanClass"><chron>June 23, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1422978886" idsrc="xmltag.org" >NS Pharma, Inc.</span> (NS Pharma; Headquarters: <location value="LU/us.nj.parmus" idsrc="xmltag.org" >Paramus, New Jersey</location>; President: <person>Yukiteru Sugiyama</person>) announced today that its parent company, <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku Co., Ltd.</span> (<span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span>; Headquarters: <location value="LU/jp..kyoto" idsrc="xmltag.org" >Kyoto, Japan</location>; President: <person>Toru Nakai</person>), has entered into a Sponsored Research Agreement (SRA) with <span value="ACORN:5020182014" idsrc="xmltag.org" >Boston Children's Hospital</span> (Headquarters: <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston, Massachusetts</location>; Chief Executive Officer: <person>Kevin B. Churchwell</person>) for the purpose of developing innovative therapeutic drugs in the field of neurology. The agreement http://www.streetinsider.com/Press+Releases/NS+Pharma+Parent+Company%2C+Nippon+Shinyaku%2C+Announces+Sponsored+Research+Agreement+with+Boston+Children%27s+Hospital/26675765.html Tue, 23 Jun 2026 07:13:00 -0400 4516 A.14229788 A.50201820 B NPPNY O.02298954 O.05105676 O.20314535 http://www.streetinsider.com/Press+Releases/NS+Pharma+Parent+Company%2C+Nippon+Shinyaku%2C+Announces+Sponsored+Research+Agreement+with+Boston+Children%27s+Hospital/26675765.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.parmus" idsrc="xmltag.org" >PARAMUS, N.J.</location></span>, <span class="legendSpanClass"><chron>June 23, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1422978886" idsrc="xmltag.org" >NS Pharma, Inc.</span> (NS Pharma; Headquarters: <location value="LU/us.nj.parmus" idsrc="xmltag.org" >Paramus, New Jersey</location>; President: <person>Yukiteru Sugiyama</person>) announced today that its parent company, <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku Co., Ltd.</span> (<span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span>; Headquarters: <location value="LU/jp..kyoto" idsrc="xmltag.org" >Kyoto, Japan</location>; President: <person>Toru Nakai</person>), has entered into a Sponsored Research Agreement (SRA) with <span value="ACORN:5020182014" idsrc="xmltag.org" >Boston Children's Hospital</span> (Headquarters: <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston, Massachusetts</location>; Chief Executive Officer: <person>Kevin B. Churchwell</person>) for the purpose of developing innovative therapeutic drugs in the field of neurology. The agreement http://www.streetinsider.com/Press+Releases/NS+Pharma+Parent+Company%2C+Nippon+Shinyaku%2C+Announces+Sponsored+Research+Agreement+with+Boston+Children%27s+Hospital/26675765.html Tue, 23 Jun 2026 07:13:00 -0400 4516 A.14229788 A.50201820 B NPPNY O.02298954 O.05105676 O.20314535 http://www.streetinsider.com/Press+Releases/NS+Pharma+Parent+Company%2C+Nippon+Shinyaku%2C+Announces+Sponsored+Research+Agreement+with+Boston+Children%27s+Hospital/26675765.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.parmus" idsrc="xmltag.org" >PARAMUS, N.J.</location></span>, <span class="legendSpanClass"><chron>June 23, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1422978886" idsrc="xmltag.org" >NS Pharma, Inc.</span> (NS Pharma; Headquarters: <location value="LU/us.nj.parmus" idsrc="xmltag.org" >Paramus, New Jersey</location>; President: <person>Yukiteru Sugiyama</person>) announced today that its parent company, <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku Co., Ltd.</span> (<span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span>; Headquarters: <location value="LU/jp..kyoto" idsrc="xmltag.org" >Kyoto, Japan</location>; President: <person>Toru Nakai</person>), has entered into a Sponsored Research Agreement (SRA) with <span value="ACORN:5020182014" idsrc="xmltag.org" >Boston Children's Hospital</span> (Headquarters: <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston, Massachusetts</location>; Chief Executive Officer: <person>Kevin B. Churchwell</person>) for the purpose of developing innovative therapeutic drugs in the field of neurology. The agreement http://www.streetinsider.com/Press+Releases/NS+Pharma+Parent+Company%2C+Nippon+Shinyaku%2C+Announces+Sponsored+Research+Agreement+with+Boston+Children%27s+Hospital/26675765.html Tue, 23 Jun 2026 07:13:00 -0400 4516 A.14229788 A.50201820 B NPPNY O.02298954 O.05105676 O.20314535 http://www.streetinsider.com/Press+Releases/NS+Pharma+Parent+Company%2C+Nippon+Shinyaku%2C+Announces+Sponsored+Research+Agreement+with+Boston+Children%27s+Hospital/26675765.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.parmus" idsrc="xmltag.org" >PARAMUS, N.J.</location></span>, <span class="legendSpanClass"><chron>June 23, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1422978886" idsrc="xmltag.org" >NS Pharma, Inc.</span> (NS Pharma; Headquarters: <location value="LU/us.nj.parmus" idsrc="xmltag.org" >Paramus, New Jersey</location>; President: <person>Yukiteru Sugiyama</person>) announced today that its parent company, <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku Co., Ltd.</span> (<span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span>; Headquarters: <location value="LU/jp..kyoto" idsrc="xmltag.org" >Kyoto, Japan</location>; President: <person>Toru Nakai</person>), has entered into a Sponsored Research Agreement (SRA) with <span value="ACORN:5020182014" idsrc="xmltag.org" >Boston Children's Hospital</span> (Headquarters: <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston, Massachusetts</location>; Chief Executive Officer: <person>Kevin B. Churchwell</person>) for the purpose of developing innovative therapeutic drugs in the field of neurology. The agreement http://www.streetinsider.com/Press+Releases/NS+Pharma+Parent+Company%2C+Nippon+Shinyaku%2C+Announces+Sponsored+Research+Agreement+with+Boston+Children%27s+Hospital/26675765.html Tue, 23 Jun 2026 07:13:00 -0400 4516 A.14229788 A.50201820 B NPPNY O.02298954 O.05105676 O.20314535 http://www.streetinsider.com/Press+Releases/NS+Pharma+Parent+Company%2C+Nippon+Shinyaku%2C+Announces+Sponsored+Research+Agreement+with+Boston+Children%27s+Hospital/26675765.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.parmus" idsrc="xmltag.org" >PARAMUS, N.J.</location></span>, <span class="legendSpanClass"><chron>June 23, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1422978886" idsrc="xmltag.org" >NS Pharma, Inc.</span> (NS Pharma; Headquarters: <location value="LU/us.nj.parmus" idsrc="xmltag.org" >Paramus, New Jersey</location>; President: <person>Yukiteru Sugiyama</person>) announced today that its parent company, <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku Co., Ltd.</span> (<span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span>; Headquarters: <location value="LU/jp..kyoto" idsrc="xmltag.org" >Kyoto, Japan</location>; President: <person>Toru Nakai</person>), has entered into a Sponsored Research Agreement (SRA) with <span value="ACORN:5020182014" idsrc="xmltag.org" >Boston Children's Hospital</span> (Headquarters: <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston, Massachusetts</location>; Chief Executive Officer: <person>Kevin B. Churchwell</person>) for the purpose of developing innovative therapeutic drugs in the field of neurology. The agreement http://www.streetinsider.com/Press+Releases/NS+Pharma+Parent+Company%2C+Nippon+Shinyaku%2C+Announces+Sponsored+Research+Agreement+with+Boston+Children%27s+Hospital/26675765.html Tue, 23 Jun 2026 07:13:00 -0400 4516 A.14229788 A.50201820 B NPPNY O.02298954 O.05105676 O.20314535 http://www.streetinsider.com/Press+Releases/NS+Pharma+Parent+Company%2C+Nippon+Shinyaku%2C+Announces+Sponsored+Research+Agreement+with+Boston+Children%27s+Hospital/26675765.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.parmus" idsrc="xmltag.org" >PARAMUS, N.J.</location></span>, <span class="legendSpanClass"><chron>June 23, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1422978886" idsrc="xmltag.org" >NS Pharma, Inc.</span> (NS Pharma; Headquarters: <location value="LU/us.nj.parmus" idsrc="xmltag.org" >Paramus, New Jersey</location>; President: <person>Yukiteru Sugiyama</person>) announced today that its parent company, <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku Co., Ltd.</span> (<span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span>; Headquarters: <location value="LU/jp..kyoto" idsrc="xmltag.org" >Kyoto, Japan</location>; President: <person>Toru Nakai</person>), has entered into a Sponsored Research Agreement (SRA) with <span value="ACORN:5020182014" idsrc="xmltag.org" >Boston Children's Hospital</span> (Headquarters: <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston, Massachusetts</location>; Chief Executive Officer: <person>Kevin B. Churchwell</person>) for the purpose of developing innovative therapeutic drugs in the field of neurology. The agreement http://www.streetinsider.com/Press+Releases/NS+Pharma+Parent+Company%2C+Nippon+Shinyaku%2C+Announces+Sponsored+Research+Agreement+with+Boston+Children%27s+Hospital/26675765.html Tue, 23 Jun 2026 07:13:00 -0400 4516 A.14229788 A.50201820 B NPPNY O.02298954 O.05105676 O.20314535 http://www.streetinsider.com/Press+Releases/NS+Pharma+Parent+Company%2C+Nippon+Shinyaku%2C+Announces+Sponsored+Research+Agreement+with+Boston+Children%27s+Hospital/26675765.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.parmus" idsrc="xmltag.org" >PARAMUS, N.J.</location></span>, <span class="legendSpanClass"><chron>June 23, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1422978886" idsrc="xmltag.org" >NS Pharma, Inc.</span> (NS Pharma; Headquarters: <location value="LU/us.nj.parmus" idsrc="xmltag.org" >Paramus, New Jersey</location>; President: <person>Yukiteru Sugiyama</person>) announced today that its parent company, <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku Co., Ltd.</span> (<span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span>; Headquarters: <location value="LU/jp..kyoto" idsrc="xmltag.org" >Kyoto, Japan</location>; President: <person>Toru Nakai</person>), has entered into a Sponsored Research Agreement (SRA) with <span value="ACORN:5020182014" idsrc="xmltag.org" >Boston Children's Hospital</span> (Headquarters: <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston, Massachusetts</location>; Chief Executive Officer: <person>Kevin B. Churchwell</person>) for the purpose of developing innovative therapeutic drugs in the field of neurology. The agreement http://www.streetinsider.com/Press+Releases/NS+Pharma+Parent+Company%2C+Nippon+Shinyaku%2C+Announces+Sponsored+Research+Agreement+with+Boston+Children%27s+Hospital/26675765.html Tue, 23 Jun 2026 07:13:00 -0400 4516 A.14229788 A.50201820 B NPPNY O.02298954 O.05105676 O.20314535 http://www.streetinsider.com/PRNewswire/NS+Pharma+Parent+Company%2C+Nippon+Shinyaku%2C+Announces+Sponsored+Research+Agreement+with+Boston+Children%27s+Hospital/26675765.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.parmus" idsrc="xmltag.org" >PARAMUS, N.J.</location></span>, <span class="legendSpanClass"><chron>June 23, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1422978886" idsrc="xmltag.org" >NS Pharma, Inc.</span> (NS Pharma; Headquarters: <location value="LU/us.nj.parmus" idsrc="xmltag.org" >Paramus, New Jersey</location>; President: <person>Yukiteru Sugiyama</person>) announced today that its parent company, <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku Co., Ltd.</span> (<span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span>; Headquarters: <location value="LU/jp..kyoto" idsrc="xmltag.org" >Kyoto, Japan</location>; President: <person>Toru Nakai</person>), has entered into a Sponsored Research Agreement (SRA) with <span value="ACORN:5020182014" idsrc="xmltag.org" >Boston Children's Hospital</span> (Headquarters: <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston, Massachusetts</location>; Chief Executive Officer: <person>Kevin B. Churchwell</person>) for the purpose of developing innovative therapeutic drugs in the field of neurology. The agreement http://www.streetinsider.com/PRNewswire/NS+Pharma+Parent+Company%2C+Nippon+Shinyaku%2C+Announces+Sponsored+Research+Agreement+with+Boston+Children%27s+Hospital/26675765.html Tue, 23 Jun 2026 07:13:00 -0400 4516 A.14229788 A.50201820 B NPPNY O.02298954 O.05105676 O.20314535 http://www.streetinsider.com/PRNewswire/NS+Pharma+Parent+Company%2C+Nippon+Shinyaku%2C+Announces+Sponsored+Research+Agreement+with+Boston+Children%27s+Hospital/26675765.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.parmus" idsrc="xmltag.org" >PARAMUS, N.J.</location></span>, <span class="legendSpanClass"><chron>June 23, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1422978886" idsrc="xmltag.org" >NS Pharma, Inc.</span> (NS Pharma; Headquarters: <location value="LU/us.nj.parmus" idsrc="xmltag.org" >Paramus, New Jersey</location>; President: <person>Yukiteru Sugiyama</person>) announced today that its parent company, <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku Co., Ltd.</span> (<span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span>; Headquarters: <location value="LU/jp..kyoto" idsrc="xmltag.org" >Kyoto, Japan</location>; President: <person>Toru Nakai</person>), has entered into a Sponsored Research Agreement (SRA) with <span value="ACORN:5020182014" idsrc="xmltag.org" >Boston Children's Hospital</span> (Headquarters: <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston, Massachusetts</location>; Chief Executive Officer: <person>Kevin B. Churchwell</person>) for the purpose of developing innovative therapeutic drugs in the field of neurology. The agreement http://www.streetinsider.com/PRNewswire/NS+Pharma+Parent+Company%2C+Nippon+Shinyaku%2C+Announces+Sponsored+Research+Agreement+with+Boston+Children%27s+Hospital/26675765.html Tue, 23 Jun 2026 07:13:00 -0400 4516 A.14229788 A.50201820 B NPPNY O.02298954 O.05105676 O.20314535 http://www.streetinsider.com/PRNewswire/NS+Pharma+Parent+Company%2C+Nippon+Shinyaku%2C+Announces+Sponsored+Research+Agreement+with+Boston+Children%27s+Hospital/26675765.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.parmus" idsrc="xmltag.org" >PARAMUS, N.J.</location></span>, <span class="legendSpanClass"><chron>June 23, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:1422978886" idsrc="xmltag.org" >NS Pharma, Inc.</span> (NS Pharma; Headquarters: <location value="LU/us.nj.parmus" idsrc="xmltag.org" >Paramus, New Jersey</location>; President: <person>Yukiteru Sugiyama</person>) announced today that its parent company, <span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku Co., Ltd.</span> (<span value="Tokyo:4516" idsrc="xmltag.org" >Nippon Shinyaku</span>; Headquarters: <location value="LU/jp..kyoto" idsrc="xmltag.org" >Kyoto, Japan</location>; President: <person>Toru Nakai</person>), has entered into a Sponsored Research Agreement (SRA) with <span value="ACORN:5020182014" idsrc="xmltag.org" >Boston Children's Hospital</span> (Headquarters: <location value="LU/us.ma.boston" idsrc="xmltag.org" >Boston, Massachusetts</location>; Chief Executive Officer: <person>Kevin B. Churchwell</person>) for the purpose of developing innovative therapeutic drugs in the field of neurology. The agreement http://www.streetinsider.com/PRNewswire/NS+Pharma+Parent+Company%2C+Nippon+Shinyaku%2C+Announces+Sponsored+Research+Agreement+with+Boston+Children%27s+Hospital/26675765.html Tue, 23 Jun 2026 07:13:00 -0400 4516 A.14229788 A.50201820 B NPPNY O.02298954 O.05105676 O.20314535